{"id":1013562,"date":"2026-10-26T13:04:52","date_gmt":"2026-10-26T17:04:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/"},"modified":"2026-10-26T13:04:52","modified_gmt":"2026-10-26T17:04:52","slug":"coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/","title":{"rendered":"Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">REDWOOD CITY, Calif., Oct.  26, 2026  (GLOBE NEWSWIRE) &#8212; <strong>Coherus Oncology, Inc<\/strong>.\u00a0(Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 2026. Starting at 5:00 p.m. Eastern Daylight Time on November 9, 2026, Coherus\u2019 management team will host a conference call and webcast to discuss financial results and provide a general business update.<\/p>\n<p>A webcast replay will be available on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sGtUESoSB4U3HulkH-y62yPKjrYRQs2cVGiStxS_b3W5P3T6xzgmHTSTkOyspBiJAhI0b5ug2tag5eEZC-ojDvF2G2DDk3uhyTGVDk14-vnvWGnatTmooG3C8Ly009xk\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.coherus.com<\/a> following the conclusion of the live conference call.<\/p>\n<p>\n        <strong>Conference Call Information<\/strong>\n      <\/p>\n<p>When: Monday, November 9, 2026, starting at 5:00 p.m. Eastern Daylight Time.<\/p>\n<p>To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sGtUESoSB4U3HulkH-y62_ts4GF9EGi6LtbpmFeUpZaCRJAx0EMmwIiITIAkv-E0FSZWaCfmWKhj4Yn4BbZrAURLZxaWZAXIpaRp4XxyegaUB7wsTrPRTqEaF1u3fTsx5A9hDtOPcUtkwjXbGP1Ul2m94dhilxflhOCRfFhfhxFmALwWoWzXt34Pa5nIzTdDPJvIRSBTTuxqo1kJidApeMMmzi6wjh6L-DZjFfoH3noq7X5_NPgq5FF2BQRJlHnk_sa0TyaHTAIPc2ByHQz3DHay12iOdONw_S_25wC0OgoXzIPXygpZ67lpSq0rohqArR73sp4mLYjJNyoe3lw_qtsDAUkVnVUKTlJWfWuPXc2MbHx8-H0v2rIqmzaVKyX8e-1ojuj5INHvOLhdL_f4S0O76MvBpzZPUGQ6Zz16R6SrOf5csurSTPKNMw9Q0UFN_Zj6hEzFdHfszJjUNTfZN_qvSgqCyELYg6o9ZSxT_sQ9A9NwyZ8bT8GS3tUGymg5DHHt0xQmFLzR22AI_-fLKCY7uUOhMn1VANF1MhePetf-5QzCVs0DeuzdCVWG6Lnjk0cEwd81nr5ThvD4pYZFUxXyTzOjj1n1DMa9mSmtSNFSaN0FsvkE88BNF8ak4fwdNuJ5d5L7IIeLm_RksBwfbnuVZ6JasLdgdl4z8A9htmW8HGoEIow4qznCBf1apVjfMH9x0ugM7VrUjjEH79Yin37pl5tUMaD5amf7U_ChDY3Y9oMLkO1k_XStzS6fbf3VRFWBhAV-pAWB2QED_ICB3A==\" rel=\"nofollow\" target=\"_blank\">https:\/\/register-conf.media-server.com\/register\/BI55798b5af6004203b3a31cfe6dff187e<\/a><\/p>\n<p>Webcast: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sGtUESoSB4U3HulkH-y62zYkKMSLLikltmUsdOtYryIg2UlBDKruNzOvjEKFsIhyrvy4ubibEFdT55ffB1m8Z77FX4zM1xFi8sbxtwqq1v31GIeTcS_C7A61fWqV-fnTM9whdtYsWXgQvDY6m8Gh956YMnt3LxSIpLZZ6MpSXh8uCpC0G85bVQ7SZ4jz-DzIaKJ34A4g95RnW1uy0Oyiq_83_I9GdAgC3JlhPT8y-PPLmriLA4HyAildYYOR3xr2IPpmmuHLyTDIo0UwUta-QtRBBopDWB2mfBqEA1w0z1jg5Zdwp0dleEpj-KXg6vQFPRxEljPOd6Nd1dAMMAFWVRZHQOdUYua969CumiYCA9kzCgCcLGR8XwetM2N_KhkRR91onANkCD_FmHCVSn5bbjZOxBWSTzztPH_BAUryMGqVh1JqhwtDIOSBQiEwjo_zygf60JDIFEmDsEVdouACvt1yoOnm1IbPyqoHejNiRlX0TpMzJESWtYxM1iEa3achq47TNcudwY9SXun2iIZ62Cs04Me3K8a-lcmF5f6-96OzMFlcweW814-OuQE4jqusVHBqVzOPOSRtaY2gYzR4FGTIYx2VZkan5Vs5aSUSkQdqp5QPiVGVvjdO9odJo20-CQTihMIV3L_BmvMi_qwEPOe0BSDcocA52Uumf6XeJ8k=\" rel=\"nofollow\" target=\"_blank\">https:\/\/edge.media-server.com\/mmc\/p\/qhta3pue<\/a><\/p>\n<p>The press release with the third quarter 2026 financial results and related materials will be available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sGtUESoSB4U3HulkH-y62yPKjrYRQs2cVGiStxS_b3XbCdRwP1SVR4FYvhqUDXdnlGTeFO-bJHZkz_XrwtdOpV-GIdjlt0ikevqlJfISXGubqFkA66rRyREy3ZJOb5Q8\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.coherus.com<\/a> before the start of the conference call.<\/p>\n<p>A live and archived webcast will be available on the \u201cInvestors\u201d section of the Coherus website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sGtUESoSB4U3HulkH-y62yPKjrYRQs2cVGiStxS_b3W9lBRpp3O7RK4vJBtcCVGWt32XITR6vF-oFj5NywQYiApzJo0lRohrcZAmmF9Vn5h2gOcWMbUjLYkyzhHfj6JcpR0Gu92iNaiX9kRg7uIUY1enMdMXFa3FuAfyI_xM0o4=\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.coherus.com\/events-presentations<\/a>.<\/p>\n<p>Please dial in15 minutes early to ensure a timely connection to the call.<\/p>\n<p>\n        <strong>Disclosure Information<\/strong>\n      <\/p>\n<p>Coherus uses the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sGtUESoSB4U3HulkH-y62yPKjrYRQs2cVGiStxS_b3X7lmc8LFmSAuVKTiDPX2yXyeFNR2sHaMqA72430lQbQfLQLWbC3d843wc_DSuAZUbN07VuVpweWc6TdIGtFFoA\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.coherus.com<\/a>\u202fwebsite as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.\u202f<\/p>\n<p>\n        <strong>About Coherus Oncology<\/strong><\/p>\n<p>Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (\u201cPD-1\u201d) inhibitor, LOQTORZI<sup>\u00ae<\/sup> (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head &amp; neck, colorectal and other cancers. The Company\u2019s strategy is to grow sales of LOQTORZI in R\/M Nasopharyngeal Carcinoma and advance the development of its two pipeline candidates in combination with LOQTORZI and through strategic partnerships.<\/p>\n<p>Coherus\u2019 innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and improve outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b\/2a studies in patients with advanced solid tumors; including head and neck squamous cell carcinoma, colorectal cancer, gastric, gastro-esophageal-junction, esophageal adenocarcinoma and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.<\/p>\n<p>LOQTORZI<sup>\u00ae<\/sup> is a registered trademark of Coherus Oncology, Inc.<br \/>\u00a92026 Coherus Oncology, Inc. All rights reserved.<\/p>\n<p>\n        <strong>Coherus Oncology Contact Information:<\/strong>\n      <\/p>\n<p>For Investors:<br \/>Carrie Graham<br \/>Vice President, Investor Relations &amp; Advocacy<br \/>IR@coherus.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjYwOCM3ODg3MTcxIzIwMTExNTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZGRlOTE2YmMtMDQyOS00OWYwLWJmZmQtNWJkNzhjN2Q2YTg3LTEwMjI3MzEtMjAyNi0xMC0yNi1lbg==\/tiny\/Coherus-Oncology.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) &#8212; Coherus Oncology, Inc.\u00a0(Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 2026. Starting at 5:00 p.m. Eastern Daylight Time on November 9, 2026, Coherus\u2019 management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https:\/\/investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, November 9, 2026, starting at 5:00 p.m. Eastern Daylight Time. To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https:\/\/register-conf.media-server.com\/register\/BI55798b5af6004203b3a31cfe6dff187e Webcast: https:\/\/edge.media-server.com\/mmc\/p\/qhta3pue The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1013562","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) &#8212; Coherus Oncology, Inc.\u00a0(Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 2026. Starting at 5:00 p.m. Eastern Daylight Time on November 9, 2026, Coherus\u2019 management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https:\/\/investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, November 9, 2026, starting at 5:00 p.m. Eastern Daylight Time. To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https:\/\/register-conf.media-server.com\/register\/BI55798b5af6004203b3a31cfe6dff187e Webcast: https:\/\/edge.media-server.com\/mmc\/p\/qhta3pue The &hellip; Continue reading &quot;Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-26T17:04:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjYwOCM3ODg3MTcxIzIwMTExNTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026\",\"datePublished\":\"2026-10-26T17:04:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\\\/\"},\"wordCount\":427,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MjYwOCM3ODg3MTcxIzIwMTExNTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\\\/\",\"name\":\"Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MjYwOCM3ODg3MTcxIzIwMTExNTg=\",\"datePublished\":\"2026-10-26T17:04:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MjYwOCM3ODg3MTcxIzIwMTExNTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MjYwOCM3ODg3MTcxIzIwMTExNTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/","og_locale":"en_US","og_type":"article","og_title":"Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026 - Market Newsdesk","og_description":"REDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) &#8212; Coherus Oncology, Inc.\u00a0(Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 2026. Starting at 5:00 p.m. Eastern Daylight Time on November 9, 2026, Coherus\u2019 management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https:\/\/investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, November 9, 2026, starting at 5:00 p.m. Eastern Daylight Time. To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https:\/\/register-conf.media-server.com\/register\/BI55798b5af6004203b3a31cfe6dff187e Webcast: https:\/\/edge.media-server.com\/mmc\/p\/qhta3pue The &hellip; Continue reading \"Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-26T17:04:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjYwOCM3ODg3MTcxIzIwMTExNTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026","datePublished":"2026-10-26T17:04:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/"},"wordCount":427,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjYwOCM3ODg3MTcxIzIwMTExNTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/","name":"Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjYwOCM3ODg3MTcxIzIwMTExNTg=","datePublished":"2026-10-26T17:04:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjYwOCM3ODg3MTcxIzIwMTExNTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjYwOCM3ODg3MTcxIzIwMTExNTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-to-report-third-quarter-2026-financial-results-on-november-9-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1013562"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013562\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1013562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1013562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1013562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}